Turn this role into an interview — a resume and cover letter built around what this employer wants.
Replimune seeks a Quality Control Technician to support daily lab operations, prep reagents, maintain equipment, manage samples, and uphold inventory in Montreal. The role may involve basic QC testing after training, ensuring accuracy and compliance with SOPs.
Ideal candidates will have GCSE-equivalent math/science background, strong time management, and proficiency with MS Word/Excel. Team players who adapt quickly will thrive in a collaborative biotech environment.
Replimune’s mission is to revolutionize cancer treatment with therapies designed to activate a powerful and durable full-body anti-tumor response, boldly transforming cancer care because
People are at the center of everything we do, and when it comes to our employees,
Replimune’s mission is to revolutionize cancer treatment with therapies designed to activate a powerful and durable full-body anti-tumor response, boldly transforming cancer care because
People are at the center of everything we do, and when it comes to our employees, we make it personal. With a deep sense of purpose, a strong and evolving culture, a competitive and forward-looking total rewards program, everyone at Replimune has a unique opportunity to impact on the lives of patients, caregivers and themselves.
The Quality Control (QC) Technician will perform various laboratory- related activities such as reagent preparation, tissue culture, equipment maintenance, sample receipt and disposal, maintenance of consumable and reagent inventory, ordering reagents and preparing reagents following relevant standard operating procedure (SOP). After adequate experience and training the role can also involves performing some simple QC testing using established test methods
Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of a novel portfolio of oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The RPx platform is designed to have a unique dual local and systemic activity consisting of direct selective virus-mediated killing of the tumor resulting in the release of tumor derived antigens and altering of the tumor microenvironment to ignite a strong and durable systemic response. The RPx product candidates are expected to be synergistic with most established and experimental cancer treatment modalities, leading to the versatility to be developed alone or combined with a variety of other treatment options. For more information, please visit www.replimune.com.
We are an Equal Opportunity Employer.